Heather Jacene, MDAuntMinnie
In an interview at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, incoming society president Heather Jacene, MD, noted a key theme of the meeting -- namely an influx of research on new radiotracers for both disease identification and treatment -- and highlighted the society's plans for next year's meeting in Washington, D.C.
Check out AuntMinnie’s full coverage of SNMMI 2026 on our ShowCast.








![(A-C) Representative whole-body maximum-intensity projection images and regional fused PET/CT images from three histologically confirmed osteosarcoma patients who underwent paired [68Ga]Ga-B7-H3-BCH PET/CT and 18F-FDGE PET/CT within seven days. (D) Multimodal imaging evaluation of Patient Three, including x-ray, MRI (T2-weighted imaging, T2WI), CT, and B7-H3 PET/CT.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/05/mei.XUQJWkpAJI.jpg?auto=format%2Ccompress&fit=crop&h=112&q=70&w=112)


![RET-targeted PET tracer highlights neuroendocrine prostate cancer tumors. Representative PET imaging shows strong tumor uptake of the RET-binding peptide tracer [⁶⁸Ga]Ga-DOTA-RET-L7 in a neuroendocrine prostate cancer (NEPC) model, supporting highly specific, high-contrast detection.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/05/screenshot-2026-05-27-205827.278Ys6PYU3.png?auto=format%2Ccompress&fit=crop&h=112&q=70&w=112)





